Mai Capital Management Immunity Bio, Inc. Transaction History
Mai Capital Management
- $13.2 Billion
- Q4 2024
A detailed history of Mai Capital Management transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Mai Capital Management holds 348 shares of IBRX stock, worth $1,266. This represents 0.0% of its overall portfolio holdings.
Number of Shares
348Holding current value
$1,266% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding IBRX
# of Institutions
229Shares Held
82.3MCall Options Held
1.02MPut Options Held
2.25M-
Vanguard Group Inc Valley Forge, PA17.3MShares$63.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$41.6 Million0.0% of portfolio
-
State Street Corp Boston, MA9.79MShares$35.6 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.01MShares$14.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.84MShares$14 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.46B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...